UF Innovate | Accelerate graduate Oragenics, a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, announced it has engaged DUCK FLATS Pharma as its U.S. Investigational New Drug (IND) readiness and regulatory execution partner to support FDA-facing preparation and clinical trial design as the Company advances its novel intranasal concussion therapy toward U.S.-based development. The engagement is intended to align the Company’s upcoming Phase 2a clinical trial in Australia with its U.S regulatory strategy.
Read more about Oragenics Partners With DUCK FLATS Pharma To Support FDA IND Readiness and Clinical Trial Design for Concussion Program.
